- Cabazitaxel in the treatment of patients with metastatic castration-resistant prostate cancer2014 | First Faculty of Medicine
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerPublication without faculty affiliation
- Current treatment options for metastatic castration-resistant prostate cancer2018 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Physical Education and Sport
- Treatment of prostate cancer in the Czech Republic in 2016: outcomes of workshops on metastatic castration-resistant prostate cancer (mCRPC)2017 | Second Faculty of Medicine
- An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA)2019 | Faculty of Medicine in Pilsen
- Enzalutamide in treatment of the metastatic castrate resistant prostate cancer2019 | First Faculty of Medicine
- Cabazitaxel for the treatment of metastatic castration-resistant prostate cancer2016 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Abiraterone in patients with metastatic castration -resistant prostate cancer without prior chemotherapy : results of a study COU -AA- 3022014 | First Faculty of Medicine
- Treatment of non‐metastatic castration‐resistant prostate cancer2023 | Third Faculty of Medicine
- Role of ARTAs in treating metastatic castration-resistant prostate cancer2019 | First Faculty of Medicine, Third Faculty of Medicine
- PARP inhibitors in treating metastatic castration-resistant prostate cancer2023 | First Faculty of Medicine
- Strategies sequential treatment of metastatic castration-resistant prostate cancer2020 | First Faculty of Medicine
- ARTA treatment of metastatic castration-resistant prostate cancer - case report2021 | First Faculty of Medicine
- Enzulutamide in treatment in patients with metastatic castration-resistant prostate cancer after previous chemotherapy2017 | First Faculty of Medicine
- Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy2016 | First Faculty of Medicine
- Treatment options of non-metastatic castration-resistant prostate cancer2018 | First Faculty of Medicine
- Non-metastatic castration-resistant prostate cancer and darolutamide - is there anything extra?2021 | Faculty of Medicine in Pilsen
- Darolutamide in the treatment of metastatic castrate-resistant prostate cancer2022 | First Faculty of Medicine
- Expanded access protocol with abiraterone acetate for metastatic castration-resistant prostate cancer post-chemoterapy - results in Czech RepublicPublication without faculty affiliation
- Enzalutamide and abiraterone in the treatment of patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy2023 | First Faculty of Medicine
- Docetaxel-Cabazitaxel-Enzalutamide Versus Docetaxel-Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer2017 | First Faculty of Medicine
- Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate2024 | Faculty of Medicine in Pilsen
- Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer2019 | First Faculty of Medicine
- Effectiveness and safety of abiraterone acetate treatment for metastatic castration-resistant prostate cancer post-chemotherapy2018 | First Faculty of Medicine
- Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial2015 | Second Faculty of Medicine
- Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience2023 | Faculty of Medicine in Pilsen
- Analysis of european patients enrolled in a global early access protocol with abiraterone acetate for metastatic castration-resistant prostate cancer progressing after chemotherapy2014 | First Faculty of Medicine
- Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer2015 | Second Faculty of Medicine
- Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer The VIABLE Phase 3 Randomized Clinical Trial2022 | Faculty of Medicine in Hradec Králové
- Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines2022 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine